Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2353-2359.e1

  Temmerman, Frederik ^a   Ho, Thien Ahn ^b   Vanslembrouck, Ragna ^a   Coudyzer, Walter ^a   Billen, Jaak ^a   Dobbels, Fabienne ^a   van Pelt, Jos ^a   Bammens, Bert ^a   Pirson, Yves ^b   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Clinical Trial; Growth Hormone Deficiency; Health Related Quality of Life; POLCA; Sarcopenia; Somatostatin Analogues

Indexed keywords

ANGIOPEPTIN; PLACEBO; SOMATOMEDIN C; CYCLOPEPTIDE; GASTROINTESTINAL AGENT; SOMATOSTATIN;

ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAT MASS; FEMALE; FOOD INTAKE; GALLBLADDER DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; INTRAABDOMINAL FAT; KIDNEY SIZE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOW DRUG DOSE; MALE; MEASUREMENT; MUSCLE ATROPHY; MUSCLE MASS; NUTRITIONAL STATUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STEATORRHEA; SUBCUTANEOUS FAT; TREATMENT DURATION; WEIGHT REDUCTION; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BELGIUM; CLINICAL TRIAL; CYSTS; HEPATOMEGALY; LIVER DISEASES; MIDDLE AGED; MUSCLE; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BELGIUM; CYSTS; FEMALE; GASTROINTESTINAL AGENTS; HEPATOMEGALY; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; MUSCLES; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84947466245     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.05.039     Document Type: Article

References (26)

1. Temmerman F., Missiaen L., Bammens B., et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011, 34:702-713.
2. Van Keimpema L., De Koning D.B., Van Hoek B., et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011, 31:92-98.
3. Schnelldorfer T., Torres V.E., Zakaria S., et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009, 250:112-118.
4. Pirenne J., Aerts R., Yoong K., et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001, 7:238-245.
5. van Keimpema L., Nevens F., Adam R., et al. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int 2011, 24:1239-1245.
6. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009, 119:3189.
7. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
8. Modlin I.M., Pavel M., Kidd M., et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 31:169-188.
9. Masyuk T.V., Masyuk A.I., Torres V.E., et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007, 132:1104-1116.
10. van Keimpema L., Nevens F., Adam R., et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137:1661-1668.
11. Hogan M.C., Masyuk T.V., Page L.J., et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010, 21:1052-1061.
12. Caroli A., Antiga L., Cafaro M., et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783-789.
13. Chrispijn M., Nevens F., Gevers T.J., et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012, 35:266-274.
14. Khan M.S., El-Khouly F., Davies P., et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011, 34:235-242.
15. Temmerman F., Gevers T., Ho T.A., et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013, 38:397-406.
16. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022074s006lbl.pdf.
17. Qian Q., Li A., King B.F., et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003, 37:164-171.
18. Temmerman F., Dobbels F., Ho T.A., et al. Development and validation of a polycystic liver disease-complaint-specific-assessment (POLCA). J Hepatol 2014, 61:1143-1150.
19. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0. DCTD, NCI, NIH, DHHS March 31, 2003 (available:), publish date: August 9, 2006. http://ctep.cancer.gov.
20. Marcora S., Lemmey A. Probable adverse effects of long term use of somatostatin analogues in patients with RA. Ann Rheum Dis 2002, 61:1117.
21. De Martino M.C., Hofland L.J., Lamberts S.W. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 2010, 182:255-280.
22. Arrazola L., Moonka D., Gish R.G., et al. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl 2006, 12:S110-S111.
23. Shen W., Punyanitya M., Wang Z., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004, 97:2333-2338.
24. Prado C.M., Baracos V.E., McCargar L.J., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009, 15:2920-2926.
25. Hogan M.C., Masyuk T.V., Page L., et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012, 27:3532-3539.
26. Boquete H.R., Sobrado P.G., Fideleff H.L., et al. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab 2003, 88:4702-4708.